display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - 1st line (L1)
atezolizumab based treatment
atezolizumab plus bevacizumab IMbrave-150

Study type: